Q2 FY2026 · ended Jun 30, 2026 · Revenue $3.38M, +4.9% YoY · Filed Aug 13, 2026
Aktis Oncology, Inc. (AKTS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $3.4 million and a net loss of $24.1 million. Free cash flow was -$21.8 million. As of Jun 30, 2026 it held $517.3 million in cash and investments and $11.2 million in total debt.
Revenue
$3.38M
+4.9% vs prior quarter
Net income
$-24.14M
-31.8% vs prior quarter
Operating cash flow
$-20.59M
+15.1% vs prior quarter
Free cash flow
$-21.85M
+16.3% vs prior quarter
EPS
$-0.44
-15.8% vs prior quarter
Dividend per share
None
Shares outstanding
53.45M
+0.1% vs prior quarter
Net cash
$506.08M
Q2 FY2026
Operating margin
-854.0%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2035832
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|
| Revenue | $3.4M | $3.2M |
| Operating income | -$28.9M | -$22.7M |
| Net income | -$24.1M | -$18.3M |
| Diluted EPS | -$0.44 | -$0.38 |
| Operating cash flow | -$20.6M | -$24.2M |
| Free cash flow | -$21.8M | -$26.1M |
| Total assets | $557.6M | $576.8M |
| Total liabilities | $72.8M | $70.7M |
| Stockholders' equity | $484.8M | $506.1M |
| Cash and investments | $517.3M | $538.5M |
| Total debt | $11.2M | $11.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 16, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
All 62 Aktis Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.